Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: A clinicopathologic study

Naoko Asano, Aya Oshiro, Keitaro Matsuo, Yoshitoyo Kagami, Fumihiro Ishida, Ritsuro Suzuki, Tomohiro Kinoshita, Yoshie Shimoyama, Jun Ichi Tamaru, Tadashi Yoshino, Kunio Kitamura, Hisashi Fukutani, Yasuo Morishima, Shigeo Nakamura

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Purpose: Classical Hodgkin's lymphoma (CHL) is characterized by Hodgkin's and Reed-Stemberg (H-RS) cells, most of which are derived from germinal-center B cells. Nevertheless, one or more markers for T cells and follicular dendritic cells (FDC) may be expressed in a minority of H-RS cells in some CHL patients, although the clinical significance of this remains controversial. The aim of this study was to clarify the association between phenotypic expression and clinical outcome in CHL. Patients and Methods: Participants were 324 consecutive CHL patients, comprising 132 patients with nodular sclerosis (NS), 35 patients with NS grade 2 (NS2), and 157 patients with mixed cellularity (MC). We evaluated the presenting features and prognosis of patients on categorization into four phenotypically defined groups: B-cell (CD20+ and/or CD79a+; n = 63), T-cell and/or cytotoxic molecules (CD3+, CD4+, CD8+, CD45RO+, TIA-1+, and/or granzyme B+; n = 27), FDC (CD21+ without B-cell marker; n = 22), and null-cell types (n = 212). Other potential prognostic factors were examined. Results: The T-cell and/or cytotoxic molecules group showed a significantly poorer prognosis than the other three groups (P <.0001). This finding was seen consistently in multivariate analyses. Morphologic subtyping (NS/NS2/MC) and Epstein-Barr virus positivity were not identified as independent prognostic factors. Conclusion: The presence of T-cell and/or cytotoxic antigens in H-RS cells may represent a poor prognostic factor in CHL, even if their expression is not regarded as lineage specific. Examination of T-cell and/or cytotoxic molecules phenotype in CHL patients is recommended as a routine pathologic practice.

Original languageEnglish
Pages (from-to)4626-4633
Number of pages8
JournalJournal of Clinical Oncology
Volume24
Issue number28
DOIs
Publication statusPublished - Oct 1 2006
Externally publishedYes

Fingerprint

Hodgkin Disease
T-Lymphocytes
Phenotype
Sclerosis
Follicular Dendritic Cells
B-Lymphocytes
Granzymes
Null Lymphocytes
CD4 Antigens
Germinal Center
Human Herpesvirus 4
Multivariate Analysis
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma : A clinicopathologic study. / Asano, Naoko; Oshiro, Aya; Matsuo, Keitaro; Kagami, Yoshitoyo; Ishida, Fumihiro; Suzuki, Ritsuro; Kinoshita, Tomohiro; Shimoyama, Yoshie; Tamaru, Jun Ichi; Yoshino, Tadashi; Kitamura, Kunio; Fukutani, Hisashi; Morishima, Yasuo; Nakamura, Shigeo.

In: Journal of Clinical Oncology, Vol. 24, No. 28, 01.10.2006, p. 4626-4633.

Research output: Contribution to journalArticle

Asano, N, Oshiro, A, Matsuo, K, Kagami, Y, Ishida, F, Suzuki, R, Kinoshita, T, Shimoyama, Y, Tamaru, JI, Yoshino, T, Kitamura, K, Fukutani, H, Morishima, Y & Nakamura, S 2006, 'Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: A clinicopathologic study', Journal of Clinical Oncology, vol. 24, no. 28, pp. 4626-4633. https://doi.org/10.1200/JCO.2006.06.5342
Asano, Naoko ; Oshiro, Aya ; Matsuo, Keitaro ; Kagami, Yoshitoyo ; Ishida, Fumihiro ; Suzuki, Ritsuro ; Kinoshita, Tomohiro ; Shimoyama, Yoshie ; Tamaru, Jun Ichi ; Yoshino, Tadashi ; Kitamura, Kunio ; Fukutani, Hisashi ; Morishima, Yasuo ; Nakamura, Shigeo. / Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma : A clinicopathologic study. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 28. pp. 4626-4633.
@article{43006e26b52a4acc97dfde15a440d96e,
title = "Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: A clinicopathologic study",
abstract = "Purpose: Classical Hodgkin's lymphoma (CHL) is characterized by Hodgkin's and Reed-Stemberg (H-RS) cells, most of which are derived from germinal-center B cells. Nevertheless, one or more markers for T cells and follicular dendritic cells (FDC) may be expressed in a minority of H-RS cells in some CHL patients, although the clinical significance of this remains controversial. The aim of this study was to clarify the association between phenotypic expression and clinical outcome in CHL. Patients and Methods: Participants were 324 consecutive CHL patients, comprising 132 patients with nodular sclerosis (NS), 35 patients with NS grade 2 (NS2), and 157 patients with mixed cellularity (MC). We evaluated the presenting features and prognosis of patients on categorization into four phenotypically defined groups: B-cell (CD20+ and/or CD79a+; n = 63), T-cell and/or cytotoxic molecules (CD3+, CD4+, CD8+, CD45RO+, TIA-1+, and/or granzyme B+; n = 27), FDC (CD21+ without B-cell marker; n = 22), and null-cell types (n = 212). Other potential prognostic factors were examined. Results: The T-cell and/or cytotoxic molecules group showed a significantly poorer prognosis than the other three groups (P <.0001). This finding was seen consistently in multivariate analyses. Morphologic subtyping (NS/NS2/MC) and Epstein-Barr virus positivity were not identified as independent prognostic factors. Conclusion: The presence of T-cell and/or cytotoxic antigens in H-RS cells may represent a poor prognostic factor in CHL, even if their expression is not regarded as lineage specific. Examination of T-cell and/or cytotoxic molecules phenotype in CHL patients is recommended as a routine pathologic practice.",
author = "Naoko Asano and Aya Oshiro and Keitaro Matsuo and Yoshitoyo Kagami and Fumihiro Ishida and Ritsuro Suzuki and Tomohiro Kinoshita and Yoshie Shimoyama and Tamaru, {Jun Ichi} and Tadashi Yoshino and Kunio Kitamura and Hisashi Fukutani and Yasuo Morishima and Shigeo Nakamura",
year = "2006",
month = "10",
day = "1",
doi = "10.1200/JCO.2006.06.5342",
language = "English",
volume = "24",
pages = "4626--4633",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "28",

}

TY - JOUR

T1 - Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma

T2 - A clinicopathologic study

AU - Asano, Naoko

AU - Oshiro, Aya

AU - Matsuo, Keitaro

AU - Kagami, Yoshitoyo

AU - Ishida, Fumihiro

AU - Suzuki, Ritsuro

AU - Kinoshita, Tomohiro

AU - Shimoyama, Yoshie

AU - Tamaru, Jun Ichi

AU - Yoshino, Tadashi

AU - Kitamura, Kunio

AU - Fukutani, Hisashi

AU - Morishima, Yasuo

AU - Nakamura, Shigeo

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Purpose: Classical Hodgkin's lymphoma (CHL) is characterized by Hodgkin's and Reed-Stemberg (H-RS) cells, most of which are derived from germinal-center B cells. Nevertheless, one or more markers for T cells and follicular dendritic cells (FDC) may be expressed in a minority of H-RS cells in some CHL patients, although the clinical significance of this remains controversial. The aim of this study was to clarify the association between phenotypic expression and clinical outcome in CHL. Patients and Methods: Participants were 324 consecutive CHL patients, comprising 132 patients with nodular sclerosis (NS), 35 patients with NS grade 2 (NS2), and 157 patients with mixed cellularity (MC). We evaluated the presenting features and prognosis of patients on categorization into four phenotypically defined groups: B-cell (CD20+ and/or CD79a+; n = 63), T-cell and/or cytotoxic molecules (CD3+, CD4+, CD8+, CD45RO+, TIA-1+, and/or granzyme B+; n = 27), FDC (CD21+ without B-cell marker; n = 22), and null-cell types (n = 212). Other potential prognostic factors were examined. Results: The T-cell and/or cytotoxic molecules group showed a significantly poorer prognosis than the other three groups (P <.0001). This finding was seen consistently in multivariate analyses. Morphologic subtyping (NS/NS2/MC) and Epstein-Barr virus positivity were not identified as independent prognostic factors. Conclusion: The presence of T-cell and/or cytotoxic antigens in H-RS cells may represent a poor prognostic factor in CHL, even if their expression is not regarded as lineage specific. Examination of T-cell and/or cytotoxic molecules phenotype in CHL patients is recommended as a routine pathologic practice.

AB - Purpose: Classical Hodgkin's lymphoma (CHL) is characterized by Hodgkin's and Reed-Stemberg (H-RS) cells, most of which are derived from germinal-center B cells. Nevertheless, one or more markers for T cells and follicular dendritic cells (FDC) may be expressed in a minority of H-RS cells in some CHL patients, although the clinical significance of this remains controversial. The aim of this study was to clarify the association between phenotypic expression and clinical outcome in CHL. Patients and Methods: Participants were 324 consecutive CHL patients, comprising 132 patients with nodular sclerosis (NS), 35 patients with NS grade 2 (NS2), and 157 patients with mixed cellularity (MC). We evaluated the presenting features and prognosis of patients on categorization into four phenotypically defined groups: B-cell (CD20+ and/or CD79a+; n = 63), T-cell and/or cytotoxic molecules (CD3+, CD4+, CD8+, CD45RO+, TIA-1+, and/or granzyme B+; n = 27), FDC (CD21+ without B-cell marker; n = 22), and null-cell types (n = 212). Other potential prognostic factors were examined. Results: The T-cell and/or cytotoxic molecules group showed a significantly poorer prognosis than the other three groups (P <.0001). This finding was seen consistently in multivariate analyses. Morphologic subtyping (NS/NS2/MC) and Epstein-Barr virus positivity were not identified as independent prognostic factors. Conclusion: The presence of T-cell and/or cytotoxic antigens in H-RS cells may represent a poor prognostic factor in CHL, even if their expression is not regarded as lineage specific. Examination of T-cell and/or cytotoxic molecules phenotype in CHL patients is recommended as a routine pathologic practice.

UR - http://www.scopus.com/inward/record.url?scp=33750598940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750598940&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.06.5342

DO - 10.1200/JCO.2006.06.5342

M3 - Article

C2 - 16954517

AN - SCOPUS:33750598940

VL - 24

SP - 4626

EP - 4633

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 28

ER -